Literature DB >> 16296721

Dry powder inhalers for pulmonary drug delivery.

H W Frijlink1, A H De Boer.   

Abstract

The pulmonary route is an interesting route for drug administration, both for effective local therapy (asthma, chronic obstructive pulmonary disease or cystic fibrosis) and for the systemic administration of drugs (e.g., peptides and proteins). Well-designed dry powder inhalers are highly efficient systems for pulmonary drug delivery. However, they are also complicated systems, the the performance of which relies on many aspects, including the design of the inhaler (e.g., resistance to air flow and the used de-agglomeration principle to generate the inhalation aerosol), the powder formulation and the air flow generated by the patient. The technical background of these aspects, and how they may be tuned in order to obtain desired performance profiles, is reviewed. In light of the technical background, new developments and possibilities for further improvements are discussed.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 16296721     DOI: 10.1517/17425247.1.1.67

Source DB:  PubMed          Journal:  Expert Opin Drug Deliv        ISSN: 1742-5247            Impact factor:   6.648


  46 in total

1.  Effects of device and formulation on in vitro performance of dry powder inhalers.

Authors:  Wallace P Adams; Sau L Lee; Robert Plourde; Robert A Lionberger; Craig M Bertha; William H Doub; Jean-Marc Bovet; Anthony J Hickey
Journal:  AAPS J       Date:  2012-04-05       Impact factor: 4.009

Review 2.  The influence of fine excipient particles on the performance of carrier-based dry powder inhalation formulations.

Authors:  Matthew D Jones; Robert Price
Journal:  Pharm Res       Date:  2006-08       Impact factor: 4.200

3.  An investigation into the dispersion mechanisms of ternary dry powder inhaler formulations by the quantification of interparticulate forces.

Authors:  Matthew D Jones; Jennifer C Hooton; Michelle L Dawson; Alan R Ferrie; Robert Price
Journal:  Pharm Res       Date:  2007-10-19       Impact factor: 4.200

Review 4.  Aerosolised antibacterials for the prevention and treatment of hospital-acquired pneumonia.

Authors:  G Christopher Wood; Joseph M Swanson
Journal:  Drugs       Date:  2007       Impact factor: 9.546

5.  The role of fines in the modification of the fluidization and dispersion mechanism within dry powder inhaler formulations.

Authors:  Jagdeep Shur; Haggis Harris; Matthew D Jones; J Sebastian Kaerger; Robert Price
Journal:  Pharm Res       Date:  2008-02-01       Impact factor: 4.200

6.  Nanoparticle deposition onto biofilms.

Authors:  J K Miller; R Neubig; C B Clemons; K L Kreider; J P Wilber; G W Young; A J Ditto; Y H Yun; A Milsted; H T Badawy; M J Panzner; W J Youngs; C L Cannon
Journal:  Ann Biomed Eng       Date:  2012-08-10       Impact factor: 3.934

7.  Multi-scale modelling of powder dispersion in a carrier-based inhalation system.

Authors:  Zhenbo Tong; Hidehiro Kamiya; Aibing Yu; Hak-Kim Chan; Runyu Yang
Journal:  Pharm Res       Date:  2014-12-17       Impact factor: 4.200

8.  Optimization of the fine particle fraction of a lyophilized lysozyme formulation for dry powder inhalation.

Authors:  Sarah Claus; Claudius Weiler; Joerg Schiewe; Wolfgang Friess
Journal:  Pharm Res       Date:  2013-04-09       Impact factor: 4.200

9.  The unusual symmetric reopening effect induced by pulmonary surfactant.

Authors:  Eiichiro Yamaguchi; Matthew J Giannetti; Matthew J Van Houten; Omid Forouzan; Sergey S Shevkoplyas; Donald P Gaver
Journal:  J Appl Physiol (1985)       Date:  2014-01-23

10.  Physico-Chemical Properties, Aerosolization and Dissolution of Co-Spray Dried Azithromycin Particles with L-Leucine for Inhalation.

Authors:  Sharad Mangal; Haichen Nie; Rongkun Xu; Rui Guo; Alex Cavallaro; Dmitry Zemlyanov; Qi Tony Zhou
Journal:  Pharm Res       Date:  2018-01-08       Impact factor: 4.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.